AKR1C3 as a target in castrate resistant prostate cancer

被引：119

作者：

Adeniji, Adegoke O. ^{[1
]}

Chen, Mo ^{[1
]}

Penning, Trevor M. ^{[1
,2
]}

机构：

[1] Univ Penn, Perelman Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA

[2] Univ Penn, Perelman Sch Med, Ctr Excellence Environm Toxicol, Philadelphia, PA 19104 USA

来源：

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY | 2013年 / 137卷

关键词：

Type 5 17 beta-hydroxysteroid dehydrogenase; Prostaglandin F synthase; Prostate cancer; Androgens; Nonsteroidal anti-inflammatory drugs; KETO REDUCTASE SUPERFAMILY; CINNAMIC ACID-DERIVATIVES; PROSTAGLANDIN-F SYNTHASE; ANDROGEN RECEPTOR; SELECTIVE INHIBITORS; 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE; ABIRATERONE ACETATE; 17-BETA-HYDROXYSTEROID-DEHYDROGENASE AKR1C3; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL;

D O I：

10.1016/j.jsbmb.2013.05.012

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Aberrant androgen receptor (AR) activation is the major driver of castrate resistant prostate cancer (CRPC). CRPC is ultimately fatal and more therapeutic agents are needed to treat this disease. Compounds that target the androgen axis by inhibiting androgen biosynthesis and or AR signaling are potential candidates for use in CRPC treatment and are currently being pursued aggressively. Aldo-keto reductase 10 (AKR1C3) plays a pivotal role in androgen biosynthesis within the prostate. It catalyzes the 17-ketoreduction of weak androgen precursors to give testosterone and 5 alpha-dihydrotestosterone. AKR1C3 expression and activity has been implicated in the development of CRPC, making it a rational target. Selective inhibition of AKR1C3 will be important, however, due to the presence of closely related isoforms. AKR1C1 and AKR1C2 that are also involved in androgen inactivation. We examine the evidence that supports the vital role of AKR1C3 in CRPC and recent developments in the discovery of potent and selective AKR1C3 inhibitors. This article is part of a Special Issue entitled 'CSR 2013'. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：136 / 149

页数：14

共 80 条

[1] Development of Potent and Selective Inhibitors of Aldo-Keto Reductase 1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase) Based on N-Phenyl-Aminobenzoates and Their Structure-Activity Relationships [J].

Adeniji, Adegoke O. ;

Twenter, Barry M. ;

Byrns, Michael C. ;

Jin, Yi ;

Chen, Mo ;

Winkler, Jeffrey D. ;

Penning, Trevor M. .

JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (05) :2311-2323

[2] Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) [J].

Adeniji, Adegoke O. ;

Twenter, Barry M. ;

Byrns, Michael C. ;

Jin, Yi ;

Winkler, Jeffrey D. ;

Penning, Trevor M. .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (05) :1464-1468

[3]

Akao Y, 2003, BIOL PHARM BULL, V26, P1057, DOI 10.1248/bpb.26.1057

[4]

[Anonymous], ENDOCRINE REV

[5]

[Anonymous], 2010, SEER cancer statistics review, 1975-2007

[6] Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

Yap, Timothy A. ;

Raynaud, Florence ;

Dowsett, Mitch ;

Settatree, Sarah ;

Barrett, Mary ;

Parker, Christopher ;

Martins, Vanessa ;

Folkerd, Elizabeth ;

Clark, Jeremy ;

Cooper, Colin S. ;

Kaye, Stan B. ;

Dearnaley, David ;

Lee, Gloria ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4563-4571

[7] Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

A'Hern, Roger ;

Parker, Christopher ;

Oommen, Nikhil Babu ;

Folkerd, Elizabeth ;

Messiou, Christina ;

Molife, L. Rhoda ;

Maier, Gal ;

Thompson, Emilda ;

Olmos, David ;

Sinha, Rajesh ;

Lee, Gloria ;

Dowsett, Mitch ;

Kaye, Stan B. ;

Dearnaley, David ;

Kheoh, Thian ;

Molina, Arturo ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) :3742-3748

[8] The backdoor pathway to dihydrotestosterone [J].

Auchus, RJ .

TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2004, 15 (09) :432-438

[9] Identification of the major oxidative 3α-hydroxysteroid dehydrogenase in human prostate that converts 5α-androstane-3α,17β-diol to 5α-dihydrotestosterone:: A potential therapeutic target for androgen-dependent disease [J].

Bauman, DR ;

Steckelbroeck, S ;

Williams, MV ;

Peehl, DM ;

Penning, TM .

MOLECULAR ENDOCRINOLOGY, 2006, 20 (02) :444-458

[10] Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: Potential antineoplastic agents that work independently of cyclooxygenase isozymes [J].

Bauman, DR ;

Rudnick, SI ;

Szewczuk, LM ;

Jin, Y ;

Gopishetty, S ;

Penning, TM .

MOLECULAR PHARMACOLOGY, 2005, 67 (01) :60-68

← 1 2 3 4 5 6 7 8 →